Think Fabrazyme first, think dedicated support

Finance assistance programs

Designed to help your eligible patients* living with a rare disease

Sanofi is committed to helping your patients navigate each state of their treatment journey. We offer a range of support services from copay assistance to personalized patient support to address your patients’ unique needs.

A female sitting down next to a healthcare provider

Copay assistance program*

The CareConnect Copay Assistance Program helps eligible patients in the United States who are prescribed Fabrazyme pay for their qualifying out-of-pocket drug costs and certain infusion-related (mixing and administration of the drug as well as infusion supplies such as saline, IV tubing, etc.) expenses, including copays, coinsurance, and deductibles.  

Patients or their caregivers interested in applying for the CareConnect Co-Pay Program will need to complete the application. The application can be downloaded below. Patients or their caregivers can also complete this application online. They can call the team at 1-800-745-4447, opt. 3, to learn how.

Download and learn more here

Patient assistance program

If your patient does not have insurance, or their insurance has denied coverage for Fabrazyme, they may be eligible to receive Fabrazyme through the CareConnect Patient Assistance Program (PAP). To see if your patient qualifies, you will need to initiate a CareConnect PAP application. This can be done on paper or online, call the team at 1-800-745-4447, opt. 3, to learn how.

A male sitting down at a desk and writing with a utensil

*Patients whose medication or infusion-related costs are covered by a state or federal health care program, including but not limited to Medicare, Medicare Part D, Medigap, Medicaid, Veterans Affairs (VA), Department of Defense (DoD), or TRICARE, are not eligible for the Co-Pay Program. Patients must live in the US or a US territory. Patients must be eligible under applicable state law(s). Other terms and conditions of the Program apply. Co-Pay Program does not cover or provide support for MD office visits/evaluations, nursing services/observation periods, blood work, x-rays or other testing, pre-medications/other medications, transportation or other related services associated with treatment. In accordance with state law, infusion-related costs are not covered for commercially insured patients residing in MA or RI. Sanofi reserves the right to modify or discontinue the programs at any time without notice. Savings may vary depending on patients’ out-of-pocket costs. All program details provided upon registration.

A male wearing a yellow long sleeve shirt, dark jeans, and white shoes walking

IMPORTANT SAFETY INFORMATION

WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS

Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy.

Initiate FABRAZYME in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions (5.1)].

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions Including Anaphylaxis

In clinical trials and post-marketing experience, approximately 1% of patients developed anaphylactic or severe hypersensitivity reactions, some life-threatening, during Fabrazyme infusion. Reactions have included localized angioedema (including swelling of the face, mouth, and throat), bronchospasm, hypotension, generalized urticaria, dysphagia, rash, dyspnea, flushing, chest discomfort, pruritus, and nasal congestion. Consider pretreating with antihistamines, antipyretics, and/or corticosteroids; however, reactions may still occur.

In Fabrazyme clinical trials, some patients developed IgE antibodies or skin test reactivity specific to Fabrazyme.

Higher incidences of hypersensitivity reactions were observed in adult patients with persistent anti-Fabrazyme antibodies, and in those with high antibody titers compared with antibody negative adult patients.
Consider testing for IgE antibodies in patients who experienced suspected hypersensitivity reactions and consider the risks and benefits of continued treatment in patients with anti-Fabrazyme IgE antibodies. Rechallenge of these patients should only occur under the direct supervision of qualified personnel, with appropriate medical support measures readily available.

Infusion-Associated Reactions

In Fabrazyme clinical trials, 59% of patients experienced infusion-associated reactions (IARs), some of which were severe. IARs are defined as those occurring on the same day as the infusion. The incidence of these reactions was higher in patients who were positive for anti-Fabrazyme antibodies than those negative for anti-Fabrazyme antibodies.

Consider pretreatment with antipyretics, antihistamines, and/or corticosteroids to reduce the risk of IARs; however, they may still occur.
If a mild or moderate IAR occurs, consider holding the infusion temporarily, decreasing the infusion rate, and/or reducing the Fabrazyme dosage. If a severe IAR occurs, discontinue Fabrazyme immediately and initiate appropriate medical treatment as needed. Assess the risks and benefits of readministering Fabrazyme and monitor patients closely if readministering.
Patients with advanced Fabry disease may have compromised cardiac function, which may predispose them to a higher risk of severe complications from IARs. Closely monitor patients with compromised cardiac function receiving Fabrazyme.

Common Adverse Reactions

Adverse reactions reported (≥20%) were upper respiratory tract infection, chills, pyrexia, headache, cough, paresthesia, fatigue, peripheral edema, dizziness, and rash.

Please see full Prescribing Information, including Boxed WARNING